Cheryl Baxter

Publications

• Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis
• HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition
• Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives
• The use of PSA as a biomarker of recent semen exposure in female reproductive health studies
• COVID-19 in Africa: Catalyzing change for sustainable development
• COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa
• Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis
• Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.
• The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance
• SARS-CoV-2 Africa dashboard for real-time COVID-19 information
• Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020–2022
• Managing and assembling population-scale data streams, tools and workflows to plan for future pandemics within the INFORM-Africa Consortium
• Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus.
• Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial
• HIV pre-exposure prophylaxis implementation in Africa: some early lessons
• Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials
• Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study
• Evaluation of miniaturized Illumina DNA preparation protocols for SARS-CoV-2 whole genome sequencing
• Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa
• Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: Study protocol for the CAPRISA 012A randomised controlled phase I trial
• Semen IgM, IgG1, and IgG3 Differentially Associate With Pro-Inflammatory Cytokines in HIV-Infected Men
• Global Expansion of SARS-CoV-2 Variants of Concern: Dispersal Patterns and Influence of Air Travel
• The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women
• Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk
• Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa
• Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages
• HIV incidence rates in adolescent girls and young women in sub-Saharan Africa
• Prevention of HIV in adolescent girls and young women: Key to an AIDS-free generation
• The dual burden of gender-based violence and HIV in adolescent girls and young women in South Africa
• Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: Study protocol for the first-in-human CAPRISA 012B phase i clinical trial
• Improving adolescent maternal health
• Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020-2022
• Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: A review
• Antibodies for HIV prevention in young women
• Genital Inflammation and the Risk of HIV Acquisition in Women
• Higher Mucosal Antibody Concentrations in Women with Genital Tract Inflammation
• Seroprevalence of hepatitis B virus: Findings from a population-based household survey in KwaZulu-Natal, South Africa
• Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women
• CAPRISA 018: A phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women
• HIV incidence trends in Africa: young women at highest risk
• Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
• Comparing SARS-CoV-2 sequencing methodologies during early phase detection of the Delta variant in South Africa
• The microbiome and HIV prevention strategies in women
• Combination HIV prevention options for young women in Africa
• Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern
• Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women
• Viral suppression among pregnant adolescents and women living with HIV in rural KwaZulu-Natal, South Africa: a cross sectional study to assess progress towards UNAIDS indicators and Implications for HIV Epidemic Control
• Higher mucosal antibody concentrations in women with genital tract inflammation
• Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
• Translating pre-exposure prophylaxis evidence into practice and public health impact
• Microbicides & their implications in HIV prevention
• Overview of the book
• Introduction
• New prevention strategies under development and investigation
• Integration of antiretroviral therapy with tuberculosis treatment
• PRO 2000: Next steps for microbicide development
• Tenofovir gel for the prevention of herpes simplex virus type 2 infection
• Utilizing nucleic acid amplification to identify acute HIV infection [4]
• Antiretroviral prophylaxis for the prevention of HIV infection: Future implementation challenges
• Antiretroviral therapy: Challenges and options in South Africa [3]
• The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis.
• Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial
• Preventing HIV infection in women: A global health imperative
• Global Epidemiology of HIV-AIDS
• Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: Study protocol for an open-label randomized controlled trial
• Adherence in the CAPRISA 004 tenofovir gel microbicide trial
• Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa
• Microbicides for prevention of HIV infection: Clinical efficacy trials
• Topical microbicides-What's new?
• Recruitment of high risk women for HIV prevention trials: Baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
• Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
• When to start antiretroviral therapy during tuberculosis treatment?
• Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies
• The need for multipurpose prevention technologies in sub-Saharan Africa
• Safety of tenofovir gel, a vaginal microbicide, in South African women: Results of the CAPRISA 004 Trial
• Overview of microbicides for the prevention of human immunodeficiency virus
• Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial
• Timing of initiation of antiretroviral drugs during tuberculosis therapy
• A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection
• Microbicides for the prevention of sexually transmitted HIV infection
• Strengthening HIV services for pregnant women: An opportunity to reduce maternal mortality rates in Southern Africa/sub-Saharan Africa
• SARS-CoV-2 Genomic Epidemiology Dashboards: A Review of Functionality and Technological Frameworks for the Public Health Response
• Understanding the Transmission Dynamics of the Chikungunya Virus in Africa